Completed PHASE3 INTERVENTIONAL 2-arm NCT01019772

Immunogenicity and Safety Study of LBVH0101 in Healthy Infants at Two, Four and Six Months of Age

A Multicentre, Comparative, Two-arm, Parallel-group, Double-blind, Randomized Phase III Study to Assess Immunogenicity and Safety of LBVH0101 (Haemophilus Influenzae Type b Tetanus Toxoid Conjugate Vaccine) Compared With Hiberix™ Vaccine in Healthy Infants at Two, Four and Six Months of Age

Sponsor: LG Life Sciences

Conditions Infectious Disease by Haemophilus Influenzae Type b

Interventions Hiberix™ Vaccine LBVH0101 (Hib vaccine)

Updated 5 times since 2017 Last updated: Nov 23, 2009 Started: Jul 31, 2007 Completion: Aug 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Infectious Disease by Haemophilus Influenzae Type b and is currently completed. LG Life Sciences leads this study, which shows 5 recorded versions since 2007 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2017 — Jan 2021 [monthly]

Completed PHASE3

First recorded

Jul 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

LG Life Sciences

Data source: LG Life Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea